Skip to main content
ARS Home » Research » Publications at this Location » Publication #154216
Title: MAREK'S DISEASE: A BIOMEDICAL MODEL FOR IDENTIFYING MOLECULAR MECHANISMS CRITICAL TO LYMPHOCYTE NEOPLASTIC TRANSFORMATION AND ANTI-LYMPHOMA IMMUNITY

Author
item BURGESS, B - MISSISSIPPI STATE UNIV
item BAATEN, B - COMPTON UK IAH
item BAXENDALE, W - INTERVET UK LTDS UK
item DAVIS, P - INTERVET UK LTDS UK
item HUNT, L - MISSISSIPPI STATE UNIV
item Lee, Lucy
item ROSS, L - COMPTON UK IAH
item SONDERMEIJER, P - INTERVET NETHERLANDS
item TARPEY, I - INTERVET UK
item YOUNG, J - COMPTON UK IAH

Submitted to: Workshop on Molecular Pathogenesis of Marek's Disease and Avian Immunology
Publication Type: Abstract Only
Publication Acceptance Date: 10/11/2002
Publication Date: 10/11/2002
Citation: Burgess, B.C., Baaten, B.J., Baxendale, W., Davis, P.J., Hunt, L., Lee, L.F., Ross, L.N., Sondermeijer, P.J., Tarpey, I., Young, J.R. 2002. Marek's disease: a biomedical model for identifying molecular mechanisms critical to lymphocyte neoplastic transformation and anti-lymphoma immunity [abstract]. Workshop on Molecular Pathogenesis of Marek's Disease and Avian Immunology. p. 40.

Interpretive Summary:

Technical Abstract: We identify that, in common with human lymphomas of both viral and non-viral etiology, the Hodgkin's disease antigen (non-mutated CD30) is over-expressed by the neoplastically-transformed cells in Marek's Disease (MD) lymphomas and other lymphomagenic chicken viruses. Data presented here showed that CD30 is immunogenic during MD and that this immunogenicity may be used to advantage in MDV vaccines. Vaccination against an aberrantly expressed host antigen in an infectious disease is novel in any system and may decrease direct immune selective pressure on pathogens and improve long-term vaccine sustainability.